Loading
Everything OnCo dates to 2019: 694 entries, 196 papers, 172 papers listed on people's pages, 118 landmarks and 85 trials reported. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
694 dated entries in OnCo fall in 2019: 196 papers, 172 papers listed on people's pages, 118 landmarks, 85 trials reported, 55 approvals, 30 regulatory events, 10 companies founded, 7 technologies, 6 journals founded, 5 financing rounds, 5 laws and regulations and 5 guideline changes.
Of those, 27 to the day, 8 to the month and 659 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
CLL/SLL, first-line and relapsed (ELEVATE-TN, ASCEND)
PIK3CA-mutant HR+/HER2- advanced breast cancer with fulvestrant after endocrine therapy
Advanced soft tissue sarcoma after chemotherapy; small cell lung cancer after at least two lines
mHSPC (TITAN)
Metastatic non-squamous non-small-cell lung cancer, with bevacizumab, carboplatin and paclitaxel.
Unresectable locally advanced or metastatic TNBC with PD-L1 expression of 1 percent or more (SP142 immune cells), with nab-paclitaxel, no prior chemotherapy for metastatic disease...
First-line advanced RCC with pembrolizumab or avelumab
Olaparib maintenance in germline BRCA-mutated metastatic pancreatic cancer
ALK-positive advanced non-small-cell lung cancer after crizotinib. TA571, published 20 March 2019, subject to the commercial arrangement.
HCC previously treated with sorafenib
Classical Hodgkin lymphoma; subsequently HCC, NSCLC, ESCC (second line 2020, first line with chemotherapy 2021), nasopharyngeal
Untreated locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer. TA595, published 14 August 2019, subject to the commercial arrangement (ARCHER 1050).
Same
Newly diagnosed, transplant-ineligible with Rd (MAIA) and VMP
Non-metastatic CRPC
Multiple myeloma in combination with other antimyeloma products (Hemady)
Advanced urothelial cancer after platinum and PD-1/PD-L1 (accelerated)
NTRK fusion solid tumours
ROS1-positive metastatic NSCLC; NTRK fusion solid tumours (≥12 years, extended to ≥1 month 2023)
mHSPC (ARCHES)
FGFR3/2-altered advanced urothelial cancer after platinum (accelerated)
Intermediate-2/high-risk primary or secondary myelofibrosis
Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia, chronic phase
CE-IVD
Newly diagnosed IDH1-mutated AML unfit for intensive chemotherapy
Same
CE mark
Beta-thalassaemia transfusion-dependent anaemia
CE mark, mammography decision support
Companion diagnostic for niraparib in HRD-positive advanced ovarian cancer
CE mark: locally advanced soft-tissue sarcoma of the limb or trunk wall, with preoperative radiotherapy
Previously untreated CLL with venetoclax, fixed duration (CLL14); with acalabrutinib (ELEVATE-TN)
Germline BRCA1/2-mutated HER2-negative locally advanced or metastatic breast cancer after an anthracycline and a taxane (OlympiAD).
Maintenance treatment of deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of fi...
Multi-gene companion diagnostic system for NSCLC
CE mark
Head and neck squamous cell carcinoma (CPS ≥1) and oesophageal squamous cell carcinoma (CPS ≥10)
Symptomatic tenosynovial giant cell tumour not amenable to surgery
Relapsed/refractory DLBCL with bendamustine-rituximab after ≥2 lines (accelerated)
CE mark
Relapsed/refractory FLT3-ITD AML
HCC with AFP ≥400 ng/mL after sorafenib
Polycythaemia vera without symptomatic splenomegaly
Steroid-refractory acute GVHD
Relapsed/refractory multiple myeloma (≥4 lines) with dexamethasone
Germline BRCA1/2-mutated HER2-negative locally advanced or metastatic breast cancer (EMBRACA); marketing authorisation issued 20 June 2019.
therascreen PIK3CA (tissue and plasma): alpelisib in breast cancer; therascreen FGFR: erdafitinib in urothelial cancer
Classical Hodgkin lymphoma (first); subsequently urothelial, NSCLC, HCC, ESCC, gastric, nasopharyngeal
HER2+ metastatic breast cancer, ≥2 prior anti-HER2 regimens
Adjuvant HER2+ breast cancer with residual disease after neoadjuvant therapy
Conditioning before allogeneic HSCT (with fludarabine) in adults and children
Refractory metastatic gastric/GEJ cancer (TAGS)
HR-positive, HER2-negative advanced breast cancer with exemestane after endocrine therapy (ACE)
Companion diagnostic for atezolizumab in PD-L1 IC ≥1% triple-negative breast cancer
Relapsed MCL (accelerated)
The regulatory events on treatment records: designations, filings, decisions, label changes and withdrawals, most of them carrying a full date.
In combination with pembrolizumab and carboplatin for first-line treatment of metastatic non-squamous NSCLC.
Subcutaneous trastuzumab-hyaluronidase (Herceptin Hylecta)
Accelerated approval with nab-paclitaxel for PD-L1-positive (SP142 IC 1 percent or more) unresectable locally advanced or metastatic TNBC on IMpassion130 progression-free survival
Unresectable or metastatic melanoma and progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
In combination with ipilimumab for BRAF V600 wild-type unresectable or metastatic melanoma. Confirmed: the accelerated approval of 2015 converted to traditional approval 3.4 years...
1) In combination with ipilimumab for unresectable or metastatic melanoma to remove the restriction for treatment of only patients with BRAF wild-type melanoma; 2) As a single agen...
In combination with paclitaxel protein-bound for unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1 (PD-L1 stained tumor-infiltrat...
Extensive-stage SCLC with chemotherapy (IMpower133)
Men with HR+/HER2- breast cancer
Treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC), that has: susceptible FGFR3 or FGFR2 genetic alterations, and progressed during or follo...
FDA Breakthrough Device designation
Adjuvant treatment of HER2+ early breast cancer with residual disease (KATHERINE)
First-line CLL with obinutuzumab (CLL14)
Humanitarian device exemption, malignant pleural mesothelioma
Recurrent or metastatic head and neck squamous cell carcinoma that progressed on or after platinum-containing chemotherapy.
In combination with bendamustine and a rituximab product for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at lea...
Complete response letter for relapsed/refractory indication (QuANTUM-R)
Metastatic SCLC with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.
In combination with dexamethasone for adults with relapsed/refractory multiple myeloma after at least 4 prior therapies and refractory to at least 2 proteasome inhibitors, 2 immuno...
Relapsed/refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic leukemia following at least 2 chemotherapy regimens.
Treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired...
In combination with pembrolizumab for advanced endometrial carcinoma not MSI-H or dMMR, with progression following systemic therapy and not candidates for curative surgery or radia...
In combination with lenvatinib for advanced endometrial carcinoma not MSI-H or dMMR, with progression following systemic therapy and not candidates for curative surgery or radiatio...
Treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
CLL/SLL
Breakthrough Therapy designation
Marketing application withdrawn after EMA objections on efficacy
Adults with locally advanced or metastatic urothelial cancer who received a PD-1 or PD-L1 inhibitor and a platinum-containing chemotherapy in the neoadjuvant, locally advanced, or...
Adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.
gBRCA metastatic pancreatic cancer maintenance (POLO)
The statutes, regulations, guidance and court rulings in the law index, dated to the year the instrument was made.
China, statute.
China, regulation.
India, regulation.
International, scheme.
United States, statute.
The dated NCCN and ESMO versions in the guideline history, with the rows each one added, removed or recategorised.
1 row recategorised. Anchored to FDA approvals of nivolumab plus ipilimumab (April 2018, CheckMate 214) and pembrolizumab plus axitinib (April 2019, KEYNOTE-426).
1 row added. Anchored to FDA approval of adjuvant trastuzumab emtansine for residual disease, May 2019 (KATHERINE).
2 rows added. Anchored to FDA approvals of axicabtagene ciloleucel (October 2017) and tisagenlecleucel (May 2018) in the third line, and polatuzumab vedotin with bendamustine-ritux...
1 row added. Anchored to FDA approval of daratumumab with lenalidomide-dexamethasone for transplant-ineligible patients, June 2019 (MAIA).
2 rows added. Anchored to FDA approvals of venetoclax plus obinutuzumab (May 2019, CLL14) and first-line acalabrutinib (November 2019, ELEVATE-TN).
The year reported on trial records, with the headline result the record gives.
Registry record NCT02441309; no result is recorded here.
Registry record NCT01975701; no result is recorded here.
Registry record NCT02747004; no result is recorded here.
Radiographic progression-free survival at 24 months 68.2 percent with apalutamide added to androgen deprivation against 47.5 percent with placebo (hazard ratio 0.48, 95 percent con...
Modified FOLFOX plus active symptom control modestly improved overall survival over active symptom control alone.
Five-year event-free survival 68.5 percent with immediate post-operative conformal radiotherapy, 61.4 percent with observation after complete resection of differentiated supratento...
Three-year progression-free survival 87.8 percent and overall survival 92.4 percent for non-germinomatous tumours given reduced whole-ventricular radiotherapy after a response to c...
Pathological complete response 16% (14 of 87) with NBTXR3 plus radiotherapy versus 8% (7 of 89) with radiotherapy alone (p=0.044).
OS 9.3 vs 5.6 months; HR 0.64.
Five-year progression-free survival 85.7 against 86.2 per cent when a negative interim scan allowed a switch to ABVD, with grade 3 to 4 anaemia falling from 69 to 28 per cent.
Investigator-assessed progression-free survival significantly longer with alectinib than crizotinib, consistent with the global ALEX trial.
No difference in progression-free survival (hazard ratio 0.93) or overall survival (1.09) against R-CHOP, with substantially more febrile neutropenia, mucositis and neuropathy.
Three-year event-free survival 83.2 percent and overall survival 94.9 percent with response- and biology-based reduction of chemotherapy; overall survival 100 percent for localised...
OS HR 1.05 (negative); drug withdrawn.
Darolutamide lengthened metastasis-free and overall survival compared with placebo with a near-placebo side-effect profile; approved in July 2019.
rPFS HR 0.39; OS HR 0.66.
Closed early after 38 of a planned 148 men were randomised; AR-V7 prevalence 8 percent (95 percent confidence interval 6 to 10) among 953 prescreened men.
Complete remission 40% vs 38.5%; not significant.
Lenalidomide plus rituximab substantially lengthened progression-free survival compared with rituximab alone; approved in May 2019.
Median overall survival 9.3 months (encorafenib-cetuximab, with or without binimetinib) vs 5.9 months (chemotherapy plus cetuximab); response rate 20% (doublet) vs 2%.
Pathological complete response 25 percent with consolidation chemotherapy against 17 percent with induction.
Median imaging-based progression-free survival 8.0 against 3.7 months (hazard ratio 0.54, 95 percent confidence interval 0.40 to 0.73) and overall survival 13.6 against 11.0 months...
OS 13.0 vs 10.3 months, HR 0.73; 3-year OS 17.6% vs 5.8%.
Daratumumab added to VTd increased stringent complete responses and lengthened progression-free survival; approved for transplant-eligible myeloma in 2019 (EU) and 2020 (US).
Nivolumab plus ipilimumab improved overall survival over chemotherapy in PD-L1-positive advanced non-small-cell lung cancer; approved in the United States in May 2020.
Local failure hazard ratio 0.32 favouring SABR; median overall survival 5 years vs 3 years.
6-year PFS 53.1% vs 21.7%; HR 0.40.
Peritoneal metastasis-free survival at 18 months 80.9 against 76.2 percent: no benefit.
Registry record NCT01886105; no result is recorded here.
Severe toxicity similar; 2-year overall survival 97.5% (cisplatin) vs 89.4% (cetuximab).
Median overall survival 3.7 months with cyclophosphamide, GVAX pancreas and CRS-207 against 4.6 months with chemotherapy in the primary cohort (hazard ratio 1.17, 95 percent confid...
Registry record NCT01876043; no result is recorded here.
6-year median PFS not reached vs 27.8 months; OS HR 0.62 (A+O).
Week 25 RECIST response 39% vs 0% (placebo); FDA approval 2019 with a liver-toxicity REMS.
Enzalutamide added to testosterone suppression improved overall survival compared with a standard non-steroidal antiandrogen.
Median symptomatic skeletal event-free survival 22.3 against 26.0 months (hazard ratio 1.122, 95 percent confidence interval 0.917 to 1.374, p=0.2636): no benefit.
Rate ratio for prostate cancer death 0.80 (95 percent confidence interval 0.65 to 0.98, adjusted p=0.04) at a median of nine years, and 0.80 (0.72 to 0.89, p<0.001) at 16 years; 1...
Registry record NCT02260817; no result is recorded here.
Perioperative FLOT improved overall survival over ECF or ECX in resectable gastric and junctional adenocarcinoma.
Three-year progression-free survival 96 per cent with four cycles of R-CHOP plus two extra rituximab doses, non-inferior to six cycles, with roughly a quarter fewer adverse events.
Median PFS 11.8 months; partial response 45%; median OS 19.2 months (single arm).
Progression-free survival at 120 months 64 percent with salvage radiotherapy plus 6 months of goserelin against 49 percent with radiotherapy alone (hazard ratio 0.54, 95 percent co...
Omitting radiotherapy after a negative interim scan cost 7.3 percentage points of five-year progression-free survival (86.1 against 93.4 per cent), with identical overall survival.
OS 21.9 vs 17.4 months, HR 0.66; CNS-PFS HR 0.32.
Median overall survival 45 vs 43 months (hazard ratio 0.90, not significant).
5-year failure-free survival 84% in both arms, non-inferior.
Individualised combinations were feasible; a matching score above 50 percent was associated with better disease control and longer progression-free and overall survival.
Within three months of immediate implant-based reconstruction: implant loss 9 percent, infection needing treatment 25 percent, return to theatre 18 percent and readmission 18 perce...
Median overall survival 8.87 months with atezolizumab and cobimetinib against 8.51 months with regorafenib (hazard ratio 1.00).
Depatuxizumab mafodotin added to radiotherapy and temozolomide did not improve overall survival in EGFR-amplified glioblastoma; stopped for futility.
6-year EFS 46.1%; intensification no benefit.
A pivotal single-arm study supporting the approval of tisagenlecleucel in relapsed or refractory large B-cell lymphoma after two or more lines.
Median overall survival 20.0 vs 12.2 months (PD-L1 50% or more, hazard ratio 0.69); 16.7 vs 12.1 months (1% or more, hazard ratio 0.81); no difference at 1 to 49%.
OS 14.9 vs 10.7 months (CPS ≥20, monotherapy); 13.0 vs 10.7 (all, with chemotherapy).
Objective response rate 45%, complete response 13%, in 53 patients with relapsed or refractory disease; FDA accelerated approval June 2018.
OS HR 0.84 final (47.2 vs 40.8 months); PFS HR 0.69.
Laparoscopic distal gastrectomy was non-inferior to open surgery for five-year overall survival in stage I gastric cancer, with fewer wound complications.
PFS HR 1.01, negative.
No clear stage shift (54.8 against 45.2 percent early stage, one-sided p = 0.24); sputum sensitivity 40.5 percent with a 32.8 percent cumulative false-positive rate, and 55 percent...
Daratumumab, lenalidomide and dexamethasone improved progression-free and later overall survival over lenalidomide and dexamethasone in transplant-ineligible newly diagnosed myelom...
Four-year overall survival 93 against 89 percent with adjuvant docetaxel added to androgen suppression and radiotherapy (hazard ratio 0.69, 90 percent confidence interval 0.49 to 0...
10-year ipsilateral breast tumour recurrence 4.6% (partial breast) vs 3.9% (whole breast); equivalence not established.
Swallowing quality of life at one year was statistically but not clinically meaningfully better after radiotherapy than after transoral robotic surgery; oncological outcomes were s...
PFS HR 0.59 overall, 0.33 HRD-positive; 5-year OS 65.5% vs 48.4% in HRD-positive.
Registry record NCT03260894; no result is recorded here.
Registry record NCT03358472; no result is recorded here.
4-year DFS 89.4% vs 89.8%, non-inferior.
Registry record NCT02453282; no result is recorded here.
Registry record NCT02872103; no result is recorded here.
PFS HR 0.53; OS HR 0.83 (not significant).
PFS HR 0.62 overall, 0.43 HRD-positive; final OS HR 1.01.
Median progression-free survival 10.5 against 4.1 years (hazard ratio 0.61) with no difference in ten-year overall survival, which was about 80 per cent in both arms.
Median overall survival 34.4 months with PROSTVAC (hazard ratio 1.01), 33.2 months with PROSTVAC and granulocyte-macrophage colony-stimulating factor (1.02) and 34.3 months with pl...
Eight-year ipsilateral breast tumour recurrence 3.0 percent with twice-daily partial-breast irradiation against 2.8 percent with whole-breast irradiation (non-inferior), with late...
Ramucirumab improved overall survival over placebo in alpha-fetoprotein-high hepatocellular carcinoma after sorafenib; approved in May 2019.
Regorafenib improved eight-week progression-free survival over placebo in relapsed osteosarcoma, with signals in the Ewing sarcoma and chondrosarcoma cohorts.
5-year overall survival 84.6% (cisplatin) vs 77.9% (cetuximab); non-inferiority not met.
5-year OS 42.3% vs 17.7% (long-term update, JCO 2020).
Registry record NCT02144077; no result is recorded here.
Median OS 18.2 months (single arm) vs 12.1 historical.
Registry record NCT02362594; no result is recorded here.
Registry record NCT02674568; no result is recorded here.
Tamoxifen 5 mg daily for three years roughly halved breast cancer events compared with placebo with few serious adverse effects.
Adding TRC105 to pazopanib did not improve progression-free survival; stopped for futility.
Primary endpoint (progression-free survival ratio against the prior line) not met in either arm; transcriptomic matching was feasible and higher matching scores tracked with longer...
The publication year on key paper records.
Earl HM, Hiller L, Vallier AL, et al. The Lancet.
Kratochwil C, Flechsig P, Lindner T, et al. Journal of Nuclear Medicine.
Hugosson J, Roobol MJ, Månsson M, et al. European Urology.
Yan Z, Cao J, Cheng H, et al. The Lancet Haematology.
Türeci O, Sahin U, Schulze-Bergkamen H, et al. Annals of Oncology.
Stock W, Luger SM, Advani AS, et al. Blood.
Engineer R, Patkar S, Lewis SC, et al. BMJ Open.
Vasan N, Baselga J, Hyman DM. Nature.
Fizazi K, Tran N, Fein L, et al. The Lancet Oncology.
Fendler WP, Calais J, Eiber M, et al. JAMA Oncology.
Merchant TE, Bendel AE, Sabin ND, et al. Journal of Clinical Oncology.
Fangusaro J, Wu S, MacDonald S, et al. Journal of Clinical Oncology.
Durham BH, Lopez Rodrigo E, Picarsic J, et al. Nature Medicine.
Perl AE, Martinelli G, Cortes JE, et al. New England Journal of Medicine.
Cardenas CE, Yang J, Anderson BM, et al. Seminars in radiation oncology.
Shaw AT, Solomon BJ, Besse B, et al. Journal of Clinical Oncology.
Hu L, Bell D, Antani S, et al. JNCI: Journal of the National Cancer Institute.
Reinert T, Henriksen TV, Christensen E, et al. JAMA Oncology.
Twist CJ, Schmidt ML, Naranjo A, et al. Journal of Clinical Oncology.
Park JR, Kreissman SG, London WB, et al. JAMA.
Chen XZ. JAMA Oncology.
Chi KN, Agarwal N, Bjartell A, et al. New England Journal of Medicine.
Fizazi K, Shore N, Tammela TL, et al. New England Journal of Medicine.
Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. Journal of Clinical Oncology.
Dillekås H, Rogers MS, Straume O. Cancer medicine.
Garcia-Murillas I, Chopra N, Comino-Mendez I, et al. JAMA Oncology.
Gyawali B, Hey SP, Kesselheim AS. JAMA Internal Medicine.
Dess RT, Hartman HE, Mahal BA, et al. JAMA Oncology.
Lee DW, Santomasso BD, Locke FL, et al. Biology of blood and marrow transplantation.
Eng C, Kim TW, Bendell J, et al. Lancet Oncology.
Leonard JP, Trneny M, Izutsu K, et al. Journal of Clinical Oncology.
Dix DB, Fernandez CV, Chi YY, et al. Journal of Clinical Oncology.
Primrose JN, Fox RP, Palmer DH, et al. The Lancet Oncology.
Mainprize T, Lipsman N, Huang Y, et al. Scientific reports.
Achrol AS, Rennert RC, Anders C, et al. Nature reviews. Disease primers.
Harbeck N, Penault-Llorca F, Cortes J, et al. Nature reviews. Disease primers.
Horwitz S, O'Connor OA, Pro B, et al. The Lancet.
Taha T, Meiri D, Talhamy S, et al. The oncologist.
IARC Monographs Vol 124 group. The Lancet Oncology.
Moreau P, Attal M, Hulin C, et al. The Lancet.
Mardones ML, Frenz P. Revista Medica de Chile.
Bernard V, Kim DU, San Lucas FA, et al. Gastroenterology.
Groot VP, Mosier S, Javed AA, et al. Clinical Cancer Research.
Lee B, Lipton L, Cohen J, et al. Annals of Oncology.
Mody K, Kasi PM, Yang J, et al. JCO Precision Oncology.
Aggarwal C, Thompson JC, Black TA, et al. JAMA Oncology.
Fischer K, Al-Sawaf O, Bahlo J, et al. New England Journal of Medicine.
Jaiswal S, Ebert BL. Science.
Dekker E, Tanis PJ, Vleugels JLA, et al. The Lancet.
Rotte A. Journal of experimental & clinical cancer research.
Menden MP, Wang D, Mason MJ, et al. Nature Communications.
Offin M, Chan JM, Tenet M, et al. Journal of Thoracic Oncology.
Roumenina LT, Daugan MV, Petitprez F, et al. Nature Reviews Cancer.
Elyada E, Bolisetty M, Laise P, et al. Cancer Discovery.
Mehanna H, Robinson M, Hartley A, et al. The Lancet.
Dudley JC, Schroers-Martin J, Lazzareschi DV, et al. Cancer Discovery.
Johnson DC, Raman SS, Mirak SA, et al. European Urology.
Jonna S, Feldman RA, Swensen J, et al. Clinical Cancer Research.
Loree JM, Anand S, Dasari A, et al. JAMA Oncology.
Bartlett NL, Wilson WH, Jung SH, et al. Journal of Clinical Oncology.
Paz-Ares L, Dvorkin M, Chen Y, et al. The Lancet.
O'Reilly EM, Oh DY, Dhani N, et al. JAMA Oncology.
Ng K, Nimeiri HS, McCleary NJ, et al. JAMA.
Hoskin PJ, Hopkins K, Misra V, et al. JAMA.
Garcia MK, Meng Z, Rosenthal DI, et al. JAMA network open.
Boevé LMS, Hulshof MCCM, Vis AN, et al. European Urology.
Pryma DA, Chin BB, Noto RB, et al. Journal of Nuclear Medicine.
Chung HC, Ros W, Delord JP, et al. Journal of Clinical Oncology.
Duffaud F, Mir O, Boudou-Rouquette P, et al. The Lancet Oncology.
Morgensztern D, Besse B, Greillier L, et al. Clinical Cancer Research.
Diamond EL, Durham BH, Ulaner GA, et al. Nature.
Marcoux N, Gettinger SN, O'Kane G, et al. Journal of Clinical Oncology.
Venkatesh HS, Morishita W, Geraghty AC, et al. Nature.
Kopetz S, Grothey A, Yaeger R, et al. New England Journal of Medicine.
Davis ID, Martin AJ, Stockler MR, et al. New England Journal of Medicine.
Roberts KJ, Bannister CA, Schrem H. Pancreatology.
Dutta U, Bush N, Kalsi D, Popli P, Kapoor VK. Chinese Clinical Oncology.
Wong CH, Siah KW, Lo AW. Biostatistics (Oxford, England).
Haslam A, Prasad V. JAMA network open.
Sanz MA, Sanz MA, Fenaux P, et al. Blood.
Aldrich MC, Mercaldo SF, Sandler KL, et al. JAMA Oncology.
Campbell KL, Winters-Stone KM, Wiskemann J, et al. Medicine and science in sports and exercise.
Ferlay J, Colombet M, Soerjomataram I, et al. International Journal of Cancer.
Badawi RD, Shi H, Hu P, et al. Journal of Nuclear Medicine.
Al-Batran SE, Homann N, Pauligk C, et al. The Lancet.
Poeschel V, Held G, Ziepert M, et al. Lancet.
Zhang Y, Chen L, Hu GQ, et al. New England Journal of Medicine.
Shroff RT, Javle MM, Xiao L, et al. JAMA Oncology.
Jiang YZ, Ma D, Suo C, et al. Cancer Cell.
Rodon J, Soria JC, Berger R, et al. Nature Medicine.
Bertucci F, Ng CKY, Patsouris A, et al. Nature.
Abida W, Cyrta J, Heller G, et al. Proceedings of the National Academy of Sciences.
Ettrich TJ, Schwerdel D, Dolnik A, et al. Scientific Reports.
Yurgelun MB, Chittenden AB, Morales-Oyarvide V, et al. Genetics in Medicine.
Kamath AA, Friedman DD, Akbari SHA, et al. Neurosurgery.
Venkataramani V, Tanev DI, Strahle C, et al. Nature.
Freites-Martinez A, Shapiro J, van den Hurk C, et al. Journal of the American Academy of Dermatology.
Cassetta L, Fragkogianni S, Sims AH, et al. Cancer Cell.
Lenz HJ, Ou FS, Venook AP, et al. Journal of Clinical Oncology.
Vuik FE, Nieuwenburg SA, Bardou M, et al. Gut.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). The Lancet.
Pietrantonio F, Miceli R, Raimondi A, et al. Journal of Clinical Oncology.
Schuetz P, Fehr R, Baechli V, et al. The Lancet.
Amit M, Abdelmeguid AS, Watcherporn T, et al. Journal of Clinical Oncology.
Greten FR, Grivennikov SI. Immunity.
Froeling FEM, Ramaswami R, Papanastasopoulos P, et al. British Journal of Cancer.
Brand DH, Tree AC, Ostler P, et al. The Lancet Oncology.
Pieters R, De Lorenzo P, Ancliffe P, et al. Journal of Clinical Oncology.
Jones MR, Williamson LM, Topham JT, et al. Clinical Cancer Research.
Schuster SJ, Bishop MR, Tam CS, et al. New England Journal of Medicine.
von Minckwitz G, Huang CS, Mano MS, et al. New England Journal of Medicine.
Burtness B, Harrington KJ, Greil R, et al. The Lancet.
Armand P, Rodig S, Melnichenko V, et al. Journal of Clinical Oncology.
Rini BI, Plimack ER, Stus V, et al. New England Journal of Medicine.
Kim HH, Han SU, Kim MC, et al. JAMA Oncology.
Vicini FA, Cecchini RS, White JR, et al. The Lancet.
DeNardo DG, Ruffell B. Nature reviews. Immunology.
Facon T, Kumar S, Plesner T, et al. New England Journal of Medicine.
Bohlius J, Bohlke K, Castelli R, et al. Journal of Clinical Oncology.
Cillessen L, Johannsen M, Speckens AEM, et al. Psycho-oncology.
Goeppert B, Roessler S, Renner M, et al. British Journal of Cancer.
Weinberg BA, Xiu J, Lindberg MR, et al. Journal of Gastrointestinal Oncology.
Sicklick JK, Kato S, Okamura R, et al. Nature Medicine.
Labrecque MP, Coleman IM, Brown LG, et al. Journal of Clinical Investigation.
Rudin CM, Poirier JT, Byers LA, et al. Nature Reviews Cancer.
Morice P, Gouy S, Leary A. New England Journal of Medicine.
Bonvalot S, Rutkowski PL, Thariat J, et al. The Lancet Oncology.
Leighl NB, Page RD, Raymond VM, et al. Clinical Cancer Research.
Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. New England Journal of Medicine.
Gillison ML, Trotti AM, Harris J, et al. The Lancet.
Robson ME, Tung N, Conte P, et al. Annals of Oncology.
Rugo HS, Finn RS, Diéras V, et al. Breast cancer research and treatment.
Ray-Coquard I, Pautier P, Pignata S, et al. New England Journal of Medicine.
Omori Y, Ono Y, Tanino M, et al. Gastroenterology.
Mok TSK, Wu YL, Kudaba I, et al. The Lancet.
Cohen EEW, Soulières D, Le Tourneau C, et al. The Lancet.
Meric-Bernstam F, Hurwitz H, Raghav KPS, et al. The Lancet Oncology.
Casasnovas RO, Bouabdallah R, Brice P, et al. Lancet Oncology.
Tap WD, Gelderblom H, Palmerini E, et al. The Lancet.
Tchekmedyian V, Sherman EJ, Dunn L, et al. Journal of Clinical Oncology.
Takahashi H, Tada Y, Saotome T, et al. Journal of Clinical Oncology.
Reidy-Lagunes D, Pandit-Taskar N, O'Donoghue JA, et al. Clinical Cancer Research.
Golan T, Hammel P, Reni M, et al. New England Journal of Medicine.
Mavaddat N, Michailidou K, Dennis J, et al. American journal of human genetics.
Wennmacker SZ, van Dijk AH, Raessens JHJ, et al. Surgical Endoscopy.
Fuchs M, Goergen H, Kobe C, et al. Journal of Clinical Oncology.
Khorana AA, McKernin SE, Berlin J, et al. Journal of Clinical Oncology.
Alyami M, Hübner M, Grass F, et al. The Lancet Oncology.
Nicolosi P, Ledet E, Yang S, et al. JAMA Oncology.
Abida W, Cheng ML, Armenia J, et al. JAMA Oncology.
González-Martín A, Pothuri B, Vergote I, et al. New England Journal of Medicine.
Park JH, Jonas SF, Bataillon G, et al. Annals of Oncology.
Armstrong AJ, Halabi S, Luo J, et al. Journal of Clinical Oncology.
Chung JH, Dewal N, Sokol E, et al. JCO Precision Oncology.
Nichols AC, Theurer J, Prisman E, et al. The Lancet Oncology.
Nakagawa K, Garon EB, Seto T, et al. The Lancet Oncology.
Hayashi H, Kurata T, Takiguchi Y, et al. Journal of Clinical Oncology.
Younes A, Sehn LH, Johnson P, et al. Journal of Clinical Oncology.
Singhi AD, George B, Greenbowe JR, et al. Gastroenterology.
Narayan RR, Creasy JM, Goldman DA, et al. Cancer.
Bardia A, Mayer IA, Vahdat LT, et al. New England Journal of Medicine.
Naumann RW, Hollebecque A, Meyer T, et al. Journal of Clinical Oncology.
Idbaih A, Canney M, Belin L, et al. Clinical Cancer Research.
Siegel RL, Miller KD, Jemal A. CA: A Cancer Journal for Clinicians.
André F, Ciruelos E, Rubovszky G, et al. New England Journal of Medicine.
Gruosso T, Gigoux M, Manem VSK, et al. Journal of Clinical Investigation.
Palma DA, Olson R, Harrow S, et al. The Lancet.
Ball D, Mai GT, Vinod S, et al. The Lancet Oncology.
Bakker MF, de Lange SV, Pijnappel RM, et al. New England Journal of Medicine.
Bachy E, Seymour JF, Feugier P, et al. Journal of Clinical Oncology.
Edelman MJ, Redman MW, Albain KS, et al. Journal of Thoracic Oncology.
Søreide K, Guest RV, Harrison EM, et al. British Journal of Surgery.
Zadik Y, Arany PR, Fregnani ER, et al. Supportive care in cancer.
Pemmaraju N, Lane AA, Sweet KL, et al. New England Journal of Medicine.
Damato BE, Dukes J, Goodall H, et al. Cancers.
Shay JW, Wright WE. Nature reviews. Genetics.
Crockett SD, Nagtegaal ID. Gastroenterology.
Lee-Six H, Olafsson S, Ellis P, et al. Nature.
Cheasley D, Wakefield MJ, Ryland GL, et al. Nature Communications.
Murphy JE, Wo JY, Ryan DP, et al. JAMA Oncology.
Bourhis J, Sozzi WJ, Jorge PG, et al. Radiotherapy and Oncology.
Metter DM, Colgan TJ, Leung ST, et al. JAMA network open.
Jiang Z, Li W, Hu X, et al. The Lancet Oncology.
Loi S, Drubay D, Adams S, et al. Journal of Clinical Oncology.
O'Reilly EM, Hechtman JF. Annals of Oncology.
Widmark A, Gunnlaugsson A, Beckman L, et al. The Lancet.
Unger JM, Vaidya R, Hershman DL, Minasian LM, Fleury ME. JNCI: Journal of the National Cancer Institute.
Scott LC, Mobley LR, Kuo TM, et al. Cancer.
Visvanathan K, Fabian CJ, Bantug E, et al. Journal of Clinical Oncology.
Rothwell DG, Ayub M, Cook N, et al. Nature Medicine.
Donadieu J, Larabi IA, Tardieu M, et al. Journal of Clinical Oncology.
Bisogno G, De Salvo GL, Bergeron C, et al. The Lancet Oncology.
Johnston RJ, Su LJ, Pinckney J, et al. Nature.
Manson JE, Cook NR, Lee IM, et al. New England Journal of Medicine.
Staaf J, Glodzik D, Bosch A, et al. Nature Medicine.
Chan EM, Shibue T, McFarland JM, et al. Nature.
The history entries editors wrote on cancer records: the dated turning points of each disease.
High-grade B-cell lymphoma with MYC and BCL2 rearrangements (double-hit lymphoma). An analysis of 157 germinal-centre diffuse large B-cell lymphomas defined a 104-gene double-hit s...
Locally advanced unresectable pancreatic ductal adenocarcinoma
Ependymoma. COG phase 2 (JCO 2019) reports outcomes by extent of resection and molecular group.
HR-positive metastatic breast cancer after CDK4/6 inhibitors
HR-positive / HER2-negative breast cancer
Intermediate-risk neuroblastoma
High-risk neuroblastoma
Neuroblastoma (paediatric)
Sarcomas (soft tissue, bone, GIST)
Soft tissue sarcoma of the extremity (localised and advanced)
Non-metastatic castration-resistant prostate cancer
Wilms tumour (nephroblastoma)
Rhabdomyosarcoma
HIV-associated (AIDS-related) lymphomas. Outcomes comparable to HIV-negative controls.
Colorectal cancer. 665 patients; encorafenib with cetuximab and binimetinib 9.0 versus 5.4 months, the doublet 8.4 months.
BRAF V600E-mutant colorectal cancer
Gallbladder cancer. Six months of capecitabine after resection of biliary tract cancer becomes the adjuvant standard.
Intrahepatic cholangiocarcinoma
Extrahepatic cholangiocarcinoma (perihilar and distal)
Adolescent and young adult cancers (ages 15 to 39)
Small-cell lung cancer
Extensive-stage small-cell lung cancer
Alveolar soft part sarcoma
Newly diagnosed multiple myeloma, transplant-eligible
Primary mediastinal (thymic) large B-cell lymphoma
Chronic lymphocytic leukaemia, first treatment
Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms. Diamond and colleagues, Nature Medicine 2019.
Erdheim-Chester disease
Pancreatic ductal adenocarcinoma. Classical tumours respond to chemotherapy three times as often as basal-like; 3,594 profiled tumours give KRAS 88% and MSI or TMB-high 0.5%; a CLI...
Colorectal cancer. From June 2019 every screening invitation in England carries a faecal immunochemical test kit, read at a threshold of 120 micrograms of haemoglobin per gram of f...
Lung cancer (all types). Mobile CT scanners parked in supermarket car parks in the areas with the highest lung cancer rates, inviting ever-smokers aged 55 to 74 through their GP re...
Tenosynovial giant cell tumour (TGCT). First systemic therapy approved for TGCT (August 2019), with a boxed hepatotoxicity warning.
NTRK fusion-positive non-small-cell lung cancer
ROS1-positive non-small-cell lung cancer
Rhabdomyosarcoma
Bladder & urothelial cancer
Muscle-invasive and advanced bladder cancer
Myeloproliferative neoplasms (PV, ET, myelofibrosis). JAKARTA; the second JAK inhibitor after an eight-year gap.
Primary myelofibrosis
Chronic lymphocytic leukaemia. Venetoclax-obinutuzumab for 12 months; ELEVATE-TN and ASCEND establish acalabrutinib.
Gastric & gastro-oesophageal junction cancer
Oesophageal and junctional adenocarcinoma
Non-Hodgkin lymphoma (all types). FLYER: three-year progression-free survival 96 per cent with four cycles of R-CHOP in young favourable disease, non-inferior to six.
Non-small-cell lung cancer. Transcription factor expression splits small-cell disease into four subtypes; in parallel, cell-free DNA is shown to be non-inferior to tissue genotypin...
Cancer of unknown primary, favourable subsets
Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma)
Cancer of unknown primary (CUP)
Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell)
Localised prostate cancer, intermediate risk
Nasopharyngeal carcinoma
Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA)
Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year)
PD-L1-high non-small-cell lung cancer without a driver mutation
Head and neck squamous cell carcinoma
Recurrent or metastatic head and neck squamous cell carcinoma
HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)
Hypopharyngeal cancer
Oral tongue and floor of mouth cancer
Head and neck squamous cell carcinoma
Endometrial cancer
Adenoid cystic carcinoma
Mesothelioma
Multiple myeloma
Newly diagnosed multiple myeloma, transplant-ineligible
Sinonasal undifferentiated carcinoma (SNUC) and SWI/SNF-deficient sinonasal carcinoma
Mucinous ovarian cancer
Microsatellite-unstable (MSI-high) gastric cancer
Testicular germ cell tumours
HER2-amplified colorectal cancer
Small intestine cancer (small bowel adenocarcinoma)
Localised small bowel adenocarcinoma (stage I to III, resected)
Hodgkin lymphoma. HD16: five-year progression-free survival 86.1 per cent without radiotherapy against 93.4 per cent with it after a negative scan.
Ovarian cancer. PRIMA (niraparib, all comers) and PAOLA-1 (olaparib + bevacizumab, HRD-positive).
Oesophageal cancer
Oropharyngeal cancer (tonsil and base of tongue)
Adrenocortical carcinoma
Clear cell renal cell carcinoma
Renal cell carcinoma
Early HER2-positive breast cancer
HER2-low and HER2-ultralow metastatic breast cancer
Localised anal squamous cell carcinoma (stage I to III)
Diffuse large B-cell lymphoma
Metastatic pancreatic ductal adenocarcinoma
BRCA or PALB2-mutant pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma. First biomarker-directed approval.
Triple-negative breast cancer (TNBC). SCAN-B whole-genome sequencing puts HRDetect-high at 59% of TNBC (Nat Med); Loi's pooled 2,148 patients fix TILs as the strongest early progno...
High-grade serous ovarian cancer
Platinum-sensitive ovarian cancer
Prostate cancer. Microsatellite instability-high or mismatch repair deficient disease is found in 3.1% of 1,033 men, with durable checkpoint inhibitor responses in 6 of 11 treated...
Osteosarcoma
Nasal cavity and paranasal sinus cancers (including esthesioneuroblastoma). Amit and colleagues, JAMA Oncol.
Polycythaemia vera (PV). The first interferon licensed for PV, on PROUD-PV and CONTINUATION-PV; FDA approval followed in November 2021.
Small-cell lung cancer
Oropharyngeal cancer (tonsil and base of tongue)
HPV-positive oropharyngeal cancer
Metastatic cancer (cancer that has spread). Randomised phase 2 trial in which stereotactic radiotherapy to all sites of oligometastatic disease was associated with longer survival...
Paediatric low-grade glioma. PBTC-029 phase 2 (Fangusaro, Lancet Oncology) reports responses in BRAF-altered and NF1-associated tumours.
Retroperitoneal sarcoma
HER2-positive breast cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Colorectal cancer. About 1% of morphologically normal colorectal crypts in middle age carry a probable driver mutation, so adenomas and cancers are the rare outcomes of a process h...
Adult T-cell leukaemia/lymphoma. The revised report added the classification of cutaneous disease, disease in the central nervous system, the management of older and transplant-ine...
Metastatic hormone-sensitive prostate cancer
Mucosal melanoma
Salivary duct carcinoma
Salivary gland cancers
Mesothelioma
Langerhans cell histiocytosis (LCH). Donadieu and colleagues (JCO) report responses in nearly all BRAF V600E children, with reactivation after stopping.
Multisystem Langerhans cell histiocytosis (with or without risk-organ involvement)
Non-Hodgkin lymphoma (all types). BCL2 G101V, found at progression in 7 of 15 paired patients and in none at study entry, lowers drug affinity about 180-fold and is detectable mont...
Triple-negative breast cancer (TNBC). Medullary carcinoma becomes a pattern of invasive carcinoma of no special type; metaplastic, adenoid cystic, apocrine and secretory carcinomas...
Breast cancer (all types). Keeps invasive carcinoma of no special type as the default group and folds the former medullary, oncocytic, lipid-rich, glycogen-rich, sebaceous and pleo...
Pancreatic ductal adenocarcinoma. Adenosquamous, colloid and undifferentiated carcinomas and the IPMN- and MCN-associated carcinomas listed as variants of ductal adenocarcinoma; so...
Gallbladder cancer. The digestive system volume standardises the nomenclature of gallbladder carcinoma and its precursors (biliary intraepithelial neoplasia, intracholecystic papil...
Grade 3 well-differentiated neuroendocrine tumour
Extrapulmonary neuroendocrine carcinoma
Goblet cell adenocarcinoma of the appendix
Mantle cell lymphoma
The since year on technology records: first use in humans or first approval, as the record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
The founded year on company records.
Taipei
Paris
London
Beijing
New York, NY
Shanghai
Watertown, Massachusetts
Shanghai
Suzhou
Lexington, MA
The funding rounds on company records, each with the source that states the figure.
GBP 1.12 million from UK health and technology angel investors (not named)
$11m
$58m. 5.75 million shares at 10 US dollars, including full exercise of the underwriters' option
$56m. Total sold per amended Form D filed August 2019
$75m. Equity offering, first sale 22 October 2019
The founded year on journal records.
American Society of Clinical Oncology
Oxford University Press
Cold Spring Harbor Laboratory, BMJ and Yale University
Oxford University Press
Radiological Society of North America
Elsevier
The selected publications each biography lists, which is a reading of that person rather than a reading of the year.
Lancet Oncology
Lancet
Lancet
Journal of Nuclear Medicine
Journal of Nuclear Medicine
Clinical Cancer Research
Annals of Oncology
Cancer Cell
Journal of Experimental & Clinical Cancer Research
The Journal of Pathology
NEJM
Pediatric Blood & Cancer
NEJM
Annals of Oncology
NEJM
JAMA Oncology
JAMA Oncology
Journal of Clinical Oncology
European Journal of Nuclear Medicine and Molecular Imaging
ASCO Educational Book
Lancet
Nature
Lancet Oncology
Nature
Indian Journal of Cancer
Journal of Experimental & Clinical Cancer Research
Gut and Liver
Cancer Immunology Research
NEJM
Clinical Cancer Research
Nature Medicine
PLOS ONE
Annals of Oncology
NEJM
Nature Medicine
European Journal of Cancer
Nature Biotechnology
Nature Reviews Drug Discovery
Global & Regional Health Technology Assessment
Annals of Oncology
Scientific Reports
The Lancet Gastroenterology & Hepatology
Nature
Lancet Oncology
Annals of Oncology
Gastroenterology
JAMA Oncology
JAMA
BMJ
Nature Reviews Cancer
Journal of the National Comprehensive Cancer Network
NEJM
NEJM
Cancer Control
Cancer Cell
The Lancet
Annals of Oncology
European Urology
Journal of Clinical Oncology
JAMA Oncology
American Journal of Human Genetics
Surgical Laparoscopy, Endoscopy & Percutaneous Techniques
Blood Advances
NEJM
European Journal of Cancer
Nature Genetics
Blood
Blood
NEJM
Journal of Vascular Surgery
Gynecologic Oncology
Journal of Clinical Oncology
PLOS ONE
JCO
Annals of Oncology
Journal of Global Oncology
Thorax
Scientific Reports
OncoImmunology
Cell
Lancet Oncology
Nature Reviews Clinical Oncology
Perfusion
Nature Biomedical Engineering
NEJM
Journal of Gastrointestinal Oncology
Clinical Neurology and Neurosurgery
Blood
Cellular and Molecular Life Sciences
Nat Genet
Cancer Cell
Gastroenterology
Journal of Clinical Oncology
Journal of Clinical Oncology
Nature Medicine
Ophthalmic Plastic & Reconstructive Surgery
New England Journal of Medicine
Lancet Oncology
Prz Menopauzalny
NEJM
Radiation Oncology
The Lancet Haematology
New England Journal of Medicine
NEJM
Cell Reports
Breast Cancer Research and Treatment
Lancet Oncology
Pancreas
Lancet
NEJM
The Lancet Oncology
Lancet
European Urology
Lancet
Annals of Oncology
Journal of Clinical Oncology
Breast Cancer Res
JCO
Annals of Oncology
The Tohoku Journal of Experimental Medicine
Annals of Surgical Oncology
Clinical Lymphoma Myeloma and Leukemia
Annals of Oncology
JCO
Journal of Clinical Oncology (ASCO Annual Meeting abstract)
Cancers
Journal of Comparative Effectiveness Research
Journal of Clinical Oncology
JAMA Oncology
Nature Genetics
Critical Reviews in Oncology/Hematology
Lancet
Lancet
Journal of Clinical Oncology
Clinical Breast Cancer
Lancet Oncology
Histopathology
Cancer Control
JAMA Oncology
Annals of Oncology
Thorax
NEJM
Arch Gynecol Obstet
Lancet
JAMA Oncology
JNCI
Nature Medicine
Nature Medicine
Journal of Experimental & Clinical Cancer Research
Cancer Drug Resistance
Clinical Cancer Research
Nature
European Urology
Annals of Surgical Oncology
International Journal of Gynecological Cancer
Journal for ImmunoTherapy of Cancer
BJU International
Medicina
NEJM
The Lancet Oncology
Lancet Oncology
New England Journal of Medicine
NEJM
Leukemia
Cancer Discovery
Breast Cancer Research and Treatment
Clinical and Translational Oncology
Lancet Oncology
Clinical and Translational Gastroenterology
Frontiers in Immunology
European Journal of Surgical Oncology
NEJM